Compound K (C-K), a
protopanaxadiol ginsenoside metabolite, was previously shown to have immunomodulatory effects. Here, we describe a novel therapeutic role for C-K in the treatment of lethal
sepsis through the modulation of
Toll-like receptor (TLR) 4-associated signalling via
glucocorticoid receptor (GR) binding. In mononuclear phagocytes, C-K significantly repressed the activation of TLR4/
lipopolysaccharide (LPS)-induced
NF-kappaB and
mitogen-activated protein kinases (MAPKs), as well as the secretion of pro-inflammatory
cytokines. However C-K did not affect the TLR3-mediated expression of
interferon-beta or the nuclear translocation of IRF-3. C-K competed with the synthetic
glucocorticoid dexamethasone for binding to GR and activated
glucocorticoid responsive
element (GRE)-containing reporter plasmids in a dose-dependent manner. In addition, the blockade of GR with either the GR antagonist
RU486 or a
siRNA against GR substantially reversed the anti-inflammatory effects of C-K. Furthermore, TLR4-dependent repression of inflammatory response genes by C-K was mediated through the disruption of p65/
interferon regulatory factor complexes. Importantly, pre- or post-treatment with C-K significantly rescued mice from Gram-negative bacterial LPS-induced lethal
shock by lowering their systemic inflammatory
cytokine levels and by reversing the lethal sequelae of
sepsis. Collectively, these results demonstrate that C-K, as a functional
ligand of GR, regulates distinct TLR4-mediated inflammatory responses, and suggest a novel
therapy for Gram-negative
septic shock.